000			02053 a2200589 4500
005			20250514002509.0
264		0	_c20011207
008			200112s 0 0 eng d
022			_a0105-2896
024	7		_a10.1034/j.1600-065x.2001.1800116.x _2doi
040			_aNLM _beng _cNLM
100	1		_aKirschfink, M
245	0	0	_aTargeting complement in therapy. _h[electronic resource]
260			_bImmunological reviews _cApr 2001
300			_a177-89 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAnaphylatoxins _xantagonists & inhibitors
650	0	4	_aAngioedema _xdrug therapy
650	0	4	_aAnimals
650	0	4	_aAnimals, Genetically Modified
650	0	4	_aAnti-Inflammatory Agents _xchemistry
650	0	4	_aAntibodies, Neoplasm _xtherapeutic use
650	0	4	_aBenzamidines
650	0	4	_aComplement Activation _xdrug effects
650	0	4	_aComplement C1 Inactivator Proteins _xtherapeutic use
650	0	4	_aComplement Inactivator Proteins _xchemistry
650	0	4	_aComplement Membrane Attack Complex _xantagonists & inhibitors
650	0	4	_aComplement System Proteins _xchemistry
650	0	4	_aDogs
650	0	4	_aDrug Design
650	0	4	_aDrug Evaluation, Preclinical
650	0	4	_aGraft Rejection _xprevention & control
650	0	4	_aGuanidines _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aImmunotherapy
650	0	4	_aInflammation _ximmunology
650	0	4	_aMacaca fascicularis
650	0	4	_aMice
650	0	4	_aNeoplasms _ximmunology
650	0	4	_aPancreatitis _xdrug therapy
650	0	4	_aRabbits
650	0	4	_aRats
650	0	4	_aReceptors, Complement _xdrug effects
650	0	4	_aReceptors, Complement 3b _xtherapeutic use
650	0	4	_aReperfusion Injury _xdrug therapy
650	0	4	_aSwine
650	0	4	_aTissue Donors
650	0	4	_aTransfection
650	0	4	_aTransplantation, Heterologous
773	0		_tImmunological reviews _gvol. 180 _gp. 177-89
856	4	0	_uhttps://doi.org/10.1034/j.1600-065x.2001.1800116.x _zAvailable from publisher's website
999			_c11344275 _d11344275